{"meshTags":["Antineoplastic Agents","Clinical Trials as Topic","Humans","Lung Neoplasms","Prognosis","Receptor Protein-Tyrosine Kinases"],"meshMinor":["Antineoplastic Agents","Clinical Trials as Topic","Humans","Lung Neoplasms","Prognosis","Receptor Protein-Tyrosine Kinases"],"publicationTypes":["Interview"],"title":"Second-generation ALK inhibitors.","pubmedId":"26353035"}